


## MARK4 inhibitor 2

Cat. No.:	HY-154986		
Molecular Formula:	C <sub>34</sub> H <sub>30</sub> N <sub>4</sub> O <sub>3</sub>		
Molecular Weight:	542.63		
Target:	AMPK		
Pathway:	Epigenetics; PI3K/Akt/mTOR		
Storage:	Powder	-20°C	3 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 100 mg/mL (184.29 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	1.8429 mL	9.2144 mL	18.4288 mL
				5 mM	0.3686 mL	1.8429 mL	3.6858 mL
				10 mM	0.1843 mL	0.9214 mL	1.8429 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: 2.5 mg/mL (4.61 mM); Clear solution; Need ultrasonic						

### BIOLOGICAL ACTIVITY

Description	MARK4 inhibitor 2 is an inhibitor of microtubule affinity-regulating kinase 4 (MARK4) with an K <sub>m</sub> of 6.3×10 <sup>-7</sup> and an IC <sub>50</sub> of 0.82 μM. MARK4 inhibitor 2 inhibits the growth of human cells and can be used for cancer research <sup>[1]</sup> .	
IC <sub>50</sub> & Target	IC50: 0.82 μM (MARK4) <sup>[1]</sup> K <sub>m</sub> : 6.3×10 <sup>-7</sup> <sup>[1]</sup>	
In Vitro	MARK4 inhibitor 2 (Compound 23a) (0-20 μM; 24 hour) inhibits the growth of HeLa, U87MG, MDA-MB-435, U251 and HGFs cells with EC <sub>50</sub> s ranging from 1.76 μM to 7.98 μM <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability Assay <sup>[1]</sup>	
	Cell Line:	HeLa, U87MG, MDA-MB-435, U251, HGFs cells
	Concentration:	0-20 μM

---

Incubation Time:	24 hours
Result:	Inhibited the growth of human cells with EC <sub>50</sub> s of 2.13, 4.13, 1.76, 7.98, 3.55 μM for HeLa, U87MG, MDA-MB-435, U251, HGFs cells, respectively. Decreased the proliferation of human cancer cells in the low micromolar range; also affects the non-cancerous HGF cells.

---

## REFERENCES

---

[1]. Maria Voura, et.al. Synthesis, Structural Modification, and Bioactivity Evaluation of Substituted Acridones as Potent Microtubule Affinity-Regulating Kinase 4 Inhibitors *ACS Pharmacology & Translational Science* 2023 6 (7), 1052-1074.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA